Audentes Therapeutics, Inc. (BOLD) News
Filter BOLD News Items
BOLD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BOLD News From Around the Web
Below are the latest news stories about BOUNDLESS BIO INC that investors may wish to consider to help them evaluate BOLD as an investment opportunity.
Boundless Bio Announces Pipeline and Leadership UpdatesCompany elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended into 2027, through anticipated clinical readout for BBI-355 and key development milestones for third ecDTx program Klaus Wagner, M.D., Ph.D., Chief Medical Officer, and Neil Abdollahian, Chief Business Officer, stepping down; James L. Freddo, M.D., to serve as Interim Chief Medical Officer SAN DIEG |
Boundless Bio to Participate in the Piper Sandler Healthcare ConferenceSAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Piper Sandler’s 36th Annual Healthcare Conference. A fireside chat session is scheduled for Wednesday, December 4, 2024, in New York, NY, at |
Boundless Bio Reports Third Quarter 2024 Financial Results and Business HighlightsEnrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with operating runway into the fourth quarter of 2026 SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers |
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare ConferenceSAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in the 2024 Guggenheim Global Healthcare Conference. A fireside chat session is scheduled for Tuesday, November 12, 2024, in Boston, MA, at 2:3 |
Boundless Bio Announces Departure of Chief Financial OfficerSAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Jami Rubin has stepped down from her role as Chief Financial Officer (CFO) for personal reasons. Boundless Bio does not plan to hire a successor CFO at this time; David Hinkle, Senior Vice President, Finance and Con |
Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Boundless Bio to Participate in the 2024 Cantor Global Healthcare ConferenceSAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, and Jami Rubin, Chief Financial Officer, will participate in the 2024 Cantor Global Healthcare Conference. A fireside chat session is scheduled for Wednesday, |
Boundless Bio, Inc. (BOLD): Why Should You Buy This New Penny Stock Now?We recently compiled a list of the 10 Best New Penny Stocks To Buy Now. In this article, we are going to take a look at where Boundless Bio, Inc. (NASDAQ:BOLD) stands against the other new penny stocks. Fears of a US recession are growing, sending stock markets down, and investors around the world are on […] |
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial ResultsBBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025 BBI-825 STARMAP clinical trial ongoing with initial proof-of-concept data expected in the second half of 2025 ECHO ecDNA diagnostic analytically validated and IRB-approved for use as a clinical trial assay in BBI-355 POTENTIATE trial Streamlined operations expected to extend operating runway into the fourth qua |
Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceSAN DIEGO, June 05, 2024--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, and Jami Rubin, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. |